LIFNano Therapeutics ^Companies

LIFNano Therapeutics is a clinical stage Nano-Bio-Med company that was founded in 2013 as a spin-out from the University of Cambridge. The organization is specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF). LIFNano Therapeutics aims to develop innovative therapies using LIF to treat a range of diseases, including autoimmune disorders and cancer. Their achievements include advancing their research to the clinical stage and developing a targeted delivery system for LIF, which has the potential to revolutionize treatment options for patients.